Literature DB >> 19424934

A population-based study of patterns of care for muscle-invasive bladder cancer in Sweden.

Staffan Jahnson1, Ole Damm, Sverker Hellsten, Sten Holmäng, Fredrik Liedberg, Börje Ljungberg, Per-Uno Malmström, Wiking Månsson, Fredrik Strömberg, Hans Wijkstöm.   

Abstract

OBJECTIVE: To analyse the management of muscle-invasive bladder cancer in a population-based national register, and specifically to investigate the role of curative therapy (i.e. cystectomy or radiotherapy) in relation to patient, tumour and hospital characteristics.
MATERIAL AND METHODS: The Swedish Bladder Cancer Register covers more than 90% of all patients in the country who have been diagnosed with such disease since 1997. Results from 1997-2003 were analysed regarding curative-intent treatment given within 3-6 months of diagnosis of muscle-invasive bladder cancer.
RESULTS: In total, 3463 patients with clinical T2-T4 bladder cancer were included in the analysis. Of those patients, 1426 (41%) received curative-intent treatment in the form of radiotherapy (285, 20%) or cystectomy (1141, 80%). Male gender, age < 76 years, favourable TNM category and registration at a high-volume hospital were associated with such treatment. Curative-intent treatment was given to significantly more patients registered at high-volume hospitals (1003/2227, 45%) than at low-volume hospitals (423/1235, 34%) (chi(2)=37.7, p<0.00001). Cystectomy was performed more often in those registered at high-volume than at low-volume hospitals (826/2227, 37%, and 316/1235, 26%, respectively, chi(2)=47.3, p<0.00001).
CONCLUSIONS: Lower rates of curative-intent treatment were found in patients registered at low-volume than at high-volume facilities, and the same was seen when comparing females with males, and patients aged 76-80 years with younger patients. Since many of these bladder cancer patients were registered at and eventually treated at hospitals handling fewer than 10 such cases annually, it seems desirable to concentrate treatment of this disease at more specialized centres.

Entities:  

Mesh:

Year:  2009        PMID: 19424934     DOI: 10.1080/00365590902909778

Source DB:  PubMed          Journal:  Scand J Urol Nephrol        ISSN: 0036-5599


  6 in total

1.  SEOM clinical guidelines for the treatment of invasive bladder cancer.

Authors:  Rafael Morales; Albert Font; Joan Carles; Dolores Isla
Journal:  Clin Transl Oncol       Date:  2011-08       Impact factor: 3.405

2.  Hospital variation in treatment patterns and oncological outcomes for patients with muscle-invasive and metastatic bladder cancer in the Netherlands.

Authors:  Daan J Reesink; Ewoudt M W van de Garde; Paul van der Nat; Diederik M Somford; Maartje Los; Simon Horenblas; Harm H E van Melick
Journal:  World J Urol       Date:  2022-04-10       Impact factor: 4.226

3.  Insight into bladder cancer care: study protocol of a large nationwide prospective cohort study (BlaZIB).

Authors:  T M Ripping; L A Kiemeney; L M C van Hoogstraten; J A Witjes; K K H Aben
Journal:  BMC Cancer       Date:  2020-05-20       Impact factor: 4.430

4.  An overview of patients with urothelial bladder cancer over the past two decades: a Surveillance, Epidemiology, and End Results (SEER) study.

Authors:  Yan Zang; Xiao Li; Yifei Cheng; Feng Qi; Ningli Yang
Journal:  Ann Transl Med       Date:  2020-12

5.  Patterns of care in patients with muscle-invasive bladder cancer - a retrospective cohort study.

Authors:  Sławomir Poletajew; Radosław Biernacki; Paweł Buraczyński; Jarosław Chojnacki; Stefan Czarniecki; Dominika Gajewska; Tomasz Pohaba; Joanna Sondka; Michał Skrzypczyk; Tomasz Suchojad; Dominik Wojtkowiak; Bogusław Zaforemski; Łukasz Zapała; Aleksandra Zemła; Piotr Radziszewski
Journal:  Contemp Oncol (Pozn)       Date:  2016-09-05

6.  Cohort profile: The Swedish National Register of Urinary Bladder Cancer (SNRUBC) and the Bladder Cancer Data Base Sweden (BladderBaSe).

Authors:  Christel Häggström; Fredrik Liedberg; Oskar Hagberg; Firas Aljabery; Viveka Ströck; Abolfazl Hosseini; Truls Gårdmark; Amir Sherif; Per-Uno Malmström; Hans Garmo; Staffan Jahnson; Lars Holmberg
Journal:  BMJ Open       Date:  2017-09-27       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.